Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18784845 | 0.92 | CYP11B1 (0.39) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL18784772 | 0.92 | CYP11B2 (0.40) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL22609668 | 0.91 | CYP19A1 (0.41) | CYP11B2CYP11B1CYP19A1KCNH2ADRA2B | |
| SCHEMBL29398982 | 0.91 | CYP19A1 (0.41) | CYP11B2CYP11B1CYP19A1KCNH2ADRA2B | |
| SCHEMBL22609633 | 0.90 | CYP11B1 (0.43) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL21771282 | 0.88 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP19A1KCNH2ADRA2B | |
| SCHEMBL30532040 | 0.88 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP19A1KCNH2ADRA2B | |
| SCHEMBL30532041 | 0.88 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP19A1KCNH2ADRA2B | |
| SCHEMBL28437704 | 0.88 | CYP19A1 (0.45) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL18784694 | 0.87 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP19A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527079-B | 2- [5- (imidazol-1-ylmethyl) pyridin-3-yl ] benzimidazole derivative compound and medicament containing the same | 日本医事物理股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-3733661-B1 | 2-[5-(IMIDAZOLE-1-YLMETHYL)PYRIDINE-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICINE INCLUDING SAME | NIHON MEDIPHYSICS CO LTD (JP) | 2023-03-15 | — | — | EP | disclosed |
| US-11266753-B2 | 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20210060186-A1 | 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20210060186-A1 | 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| EP-3733661-A1 | 2-[5-(IMIDAZOLE-1-YLMETHYL)PYRIDINE-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICINE INCLUDING SAME | Nihon Medi-Physics Co., Ltd (JP) | 2020-11-04 | — | — | EP | disclosed |
| CN-111527079-A | 2- [5- (imidazol-1-ylmethyl) pyridin-3-yl ] benzimidazole derivative compound and medicine comprising the same | 日本医事物理股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060186-A1 | 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME | NPM1, ABL1, FLI1 | CYP11B2 72/4885CYP11B1 167/4885CYP19A1 2064/4885 |
| US-11266753-B2 | 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same | NPM1, XDH, ABL1 | CYP11B2 17/4885CYP11B1 49/4885CYP19A1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.